Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier


    Keynote presentations from the recipients of the 2016 iCMLf Prizes

    At the 18th Annual John Goldman Conference on CML in Houston the iCMLf Directors awarded the Foundation’s 2016 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.

    Collage 2016 Keynotes Prizes


    • 2016 Rowley Prize: Professor Nora Heisterkamp 
    • 2016 Goldman Prize: Professor Hagop Kantarjian
    • 2016 iCMLf Prize: Associate Professor Susan Branford
    Heisterkamp Keynote JGM 2016




    Keynote Rowley Prize 2016:

    Evolution in our leukemia research: From identification of BCR/ABL fusion to carbohydrate-mediated protection by the bone marrow environment
    Professor Nora Heisterkamp

    Children's Center for Cancer and Blood Diseases, Children's Hospital in Los Angeles (USA)

    • Localization of human ABL on chromosome 9
    • ABL is located on the Ph chromosome
    • Cloning of part of human c-ABL
    • Sequencing of pTyr site of c-ABL
    • Breakpoint in the 5' region of c-ABL in CML DNA
    • Use of chimeric 22/9 fragment to clone part of chromosome 9
    • Ph breakpoints are clustered in a breakpoint cluster region 
    • BCR or 'PHL' is part of a gene
    • A chimeric BCR-ABL mRNA is made
    • Research 1987 and after
    Kantarjian Keynote JGM 2016  

    Keynote Goldman Prize 2016:

    Chronic Myeloid Leukemia beyond 2016: Important Questions
    Professor Hagop Kantarjian

    Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston (USA)

    • CML - few key studies
    • CML survival rates
    • CML - important questions
    • CML frontline RX
    • Optimal dose for second TKI's
    • CML therapy in 2016
    • CML - potential molecular cures
    • Cost-benefit of TKI's
    • Criteria for response/failure and change of RX
    • CML - role and timing of allo SCT
    • Therapy of CML transformation
    • Detection of mutations in CML
    Please note: 
    There is currently no web stream available of this presentation and you can only see the slides. 



    Branford keynote JGM 2016   

    Keynote iCMLf Prize 2016:

    Challenges for monitoring patients in emerging economic regions
    Associate Professor Susan Branford

    Centre for Cancer Biology, SA Pathology and Universities of Adelaide and South Australia (Australia)

    • Quantitative PCR - from the 1st patient tested to treatment-free remission
    • First time monitoring for 30 patients from the Philippines in 2011
    • Point of care monitoring
    • The evolution of BCR-ABL1 molecular testing from 2000-2016
    • iCMLf supporting clinician and scientist training in expert centres
    • Testing in the Philippines in 2016
    • 30 patients tested for mutations in Adelaide 2015
    • Molecular monitoring - unmet needs
    • CML monitoring circa 2016 - a future outlook